Andrew Zelenetz, MD, PhD, discusses how patient characteristics and disease history play into treatment strategy for follicular lymphoma.
Guidelines | NCCN Guideline Update for Follicular Lymphoma: Translating NCCN Updates Into Follicular Lymphoma Practice
NCCN Guideline Update for Follicular Lymphoma: Translating NCCN Updates Into Follicular Lymphoma Practice
Videos
Andrew Zelenetz, MD, PhD, addresses the potential for CD19 antigen loss, the lack of robust data, and the influence of newer, highly efficacious combination therapies on the sequencing decisions in follicular lymphoma.
Advertisement
Advertisement
Trending on AJMC
1
Fixed-Duration Epcoritamab Plus Chemotherapy Yields Response, Remissions in DLBCL
2
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
3
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
4
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
5
